This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Rebecca L. Milsap, PharmD; Peter A. M. Auld, MD

JAMA. 1980;243(2):144-145.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

DIAZOXIDE, a nondiuretic thiazide, when injected intravenously (IV) is a potent arteriolar dilator effective in the treatment of severe hypertension associated with pregnancy.^1,2 Animal studies have shown that diazoxide crosses the placenta, causing fetal hyperglycemia^3,4 and destruction of pancreatic islet cells.⁵ An infant experienced severe persistent postnatal hyperglycemia after in utero exposure to diazoxide.

Report of a Case

A 31-year-old woman, gravida 1, para 0, noted to have proteinuria (2+) and blood pressure (BP) of 130/90 mm Hg at approximately 30 weeks' gestation, was hospitalized at 33 weeks with complaints of abdominal pain. A BP of 200/130 mm Hg, with 3+ reflexes, ankle edema, and proteinuria (3+) were present. Mild uterine contractions ensued, with BP to 240/140 mm Hg. The mother was initially treated with intramuscular magnesium sulfate and hydralazine hydrochloride, with reduction in BP to 194/130 mm Hg. Approximately 2 1/2 hours before delivery, furosemide, 40 . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Pharmacy (Dr Milsap) and the Perinatology Center, Department of Pediatrics (Dr Auld), The New York Hospital-Cornell Medical Center, New York.

Footnotes
Reprint requests to Department of Pediatrics, New York Hospital-Cornell Medical Center, 525 E 68th St, New York, NY 10021 (Dr Auld).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?